These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 20577269)

  • 1. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.
    Zolla-Pazner S; Cardozo T
    Nat Rev Immunol; 2010 Jul; 10(7):527-35. PubMed ID: 20577269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GP120: target for neutralizing HIV-1 antibodies.
    Pantophlet R; Burton DR
    Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site.
    Conti S; Kaczorowski KJ; Song G; Porter K; Andrabi R; Burton DR; Chakraborty AK; Karplus M
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VLP vaccines and effects of HIV-1 Env protein modifications on their antigenic properties].
    Vzorov AN; Compans RW
    Mol Biol (Mosk); 2016; 50(3):406-15. PubMed ID: 27414779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein.
    Carlos MP; Anderson DE; Gardner MB; Torres JV
    AIDS Res Hum Retroviruses; 2000 Jan; 16(2):153-61. PubMed ID: 10659054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to HIV-1 induced by immunization.
    McCoy LE; Weiss RA
    J Exp Med; 2013 Feb; 210(2):209-23. PubMed ID: 23401570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Jun; 5(3):347-63. PubMed ID: 16827619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.
    Spurrier B; Sampson J; Gorny MK; Zolla-Pazner S; Kong XP
    J Virol; 2014 Apr; 88(8):4100-12. PubMed ID: 24478429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in HIV vaccine development.
    Hsu DC; O'Connell RJ
    Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
    Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent strategies targeting HIV glycans in vaccine design.
    Horiya S; MacPherson IS; Krauss IJ
    Nat Chem Biol; 2014 Dec; 10(12):990-9. PubMed ID: 25393493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
    Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
    Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.